Stringent Regulations Hinder International Trials In China: Trade Groups

 
• By Dexter Jie Yan

Any delays caused by unpredictable regulatory reviews related to the export of genetic materials threaten to derail the inclusion of China in international clinical trials, caution two trade groups representing the pharma industry in the country.

lack of transparency and predictability in Chinese regulations
Two trade groups call out China's tight study regulations for lack of transparency and predictability. • Source: Alamy

More from China

More from Asia